CR20230408A - Compuestos moduladores de gcn2 y usos de los mismos - Google Patents

Compuestos moduladores de gcn2 y usos de los mismos

Info

Publication number
CR20230408A
CR20230408A CR20230408A CR20230408A CR20230408A CR 20230408 A CR20230408 A CR 20230408A CR 20230408 A CR20230408 A CR 20230408A CR 20230408 A CR20230408 A CR 20230408A CR 20230408 A CR20230408 A CR 20230408A
Authority
CR
Costa Rica
Prior art keywords
gcn2
modulating compounds
modulating
compounds
diseases
Prior art date
Application number
CR20230408A
Other languages
English (en)
Inventor
Savithri Ramurthy
Mark J Mulvihill
Bradley Sherborne
Benjamin Rahemtulla
Christopher G Thomson
Eric P A Talbot
Original Assignee
Hibercell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hibercell Inc filed Critical Hibercell Inc
Publication of CR20230408A publication Critical patent/CR20230408A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Holo Graphy (AREA)
  • Liquid Crystal Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En la presente se proporcionan compuestos, composiciones y métodos útiles para modular la actividad de GCN2 y para tratar condiciones, enfermedades y trastornos relacionados (por ejemplo, cáncer y enfermedades neurodegenerativas).
CR20230408A 2021-01-22 2022-01-21 Compuestos moduladores de gcn2 y usos de los mismos CR20230408A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163140314P 2021-01-22 2021-01-22
PCT/US2022/013383 WO2022159746A1 (en) 2021-01-22 2022-01-21 Gcn2 modulating compounds and uses thereof

Publications (1)

Publication Number Publication Date
CR20230408A true CR20230408A (es) 2024-05-07

Family

ID=80446635

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230408A CR20230408A (es) 2021-01-22 2022-01-21 Compuestos moduladores de gcn2 y usos de los mismos

Country Status (14)

Country Link
US (1) US20240083897A1 (es)
EP (1) EP4281182A1 (es)
JP (1) JP2024504364A (es)
KR (1) KR20240021143A (es)
CN (1) CN117203206A (es)
AU (1) AU2022210760A1 (es)
BR (1) BR112023014723A2 (es)
CA (1) CA3209124A1 (es)
CO (1) CO2023010940A2 (es)
CR (1) CR20230408A (es)
IL (1) IL304611A (es)
MX (1) MX2023008589A (es)
PE (1) PE20240691A1 (es)
WO (1) WO2022159746A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202008749D0 (en) 2020-06-09 2020-07-22 Ip2Ipo Innovations Ltd Novel compounds
WO2023230567A1 (en) * 2022-05-25 2023-11-30 Hibercell, Inc. Gcn2 modulator for treating cancer
WO2024077092A1 (en) * 2022-10-04 2024-04-11 Hibercell, Inc. Gcn2 inhibitor for treating metastases
IL322199A (en) * 2023-01-20 2025-09-01 Hibercell Inc Crystalline forms of 6-(3-((5-chloro-2-methoxypyridine)-3-sulfonamido)-6,2-difluorophenyl)-N-methylimidazo[1, 5-A]pyrazine-1-carboxamide and methods of use are
WO2025122985A1 (en) * 2023-12-08 2025-06-12 Hibercell, Inc. Methods of treating acute myeloid leukemia using combinations of gcn2 modulators, venetoclax, and azacitidine
WO2025137710A1 (en) * 2023-12-22 2025-06-26 Hibercell, Inc. Methods of treating cancer using combinations of gcn2 modulators and belzutifan

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004279427B2 (en) * 2003-10-08 2008-07-03 Irm Llc Compounds and compositions as protein kinase inhibitors
ES2422263T3 (es) * 2008-12-19 2013-09-10 Nerviano Medical Sciences Srl Pirazoles bicíclicos como inhibidores de la proteinquinasa
HRP20241768T1 (hr) * 2016-08-10 2025-02-28 Takeda Pharmaceutical Company Limited Heterociklički spoj
JP7229257B2 (ja) * 2018-01-29 2023-02-28 メルク パテント ゲーエムベーハー Ｇｃｎ２阻害剤およびその使用
US20220388964A1 (en) * 2019-04-12 2022-12-08 Hibercell, Inc. (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions
JP2023514328A (ja) * 2020-02-17 2023-04-05 アレスタ・セラピューティクス・ベスローテン・フェンノートシャップ Ｇｃｎ２モジュレーター化合物

Also Published As

Publication number Publication date
JP2024504364A (ja) 2024-01-31
KR20240021143A (ko) 2024-02-16
CA3209124A1 (en) 2022-07-28
CO2023010940A2 (es) 2023-12-11
CN117203206A (zh) 2023-12-08
BR112023014723A2 (pt) 2023-10-03
US20240083897A1 (en) 2024-03-14
EP4281182A1 (en) 2023-11-29
IL304611A (en) 2023-09-01
WO2022159746A1 (en) 2022-07-28
AU2022210760A1 (en) 2023-09-07
MX2023008589A (es) 2023-08-09
PE20240691A1 (es) 2024-04-10

Similar Documents

Publication Publication Date Title
MX2023008589A (es) Compuestos moduladores de gcn2 y usos de los mismos.
WO2020163823A3 (en) Therapeutic agents and methods of treatment
PH12021552759A1 (en) Substituted cycloalkyls as modulators of the integrated stress pathway
AU2019362061A8 (en) Androgen receptor modulators and methods for their use
MX2020011234A (es) Moduladores de receptor similar al dominio de oligomerizacion de union a nucleotidos que contiene dominio de pirina 3 (nlrp3).
MY209609A (en) Immunomodulators, compositions and methods thereof
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
EP4520328A3 (en) Heterocyclic compounds as immunomodulators
MX2023012245A (es) Compuestos, composiciones y metodos para el tratamiento del cancer.
WO2025049274A3 (en) Tetracyclic derivatives, compositions and methods thereof
MX2023005928A (es) Moduladores de malt-1.
MY207223A (en) Prodrug modulators of the integrated stress pathway
MX2023009682A (es) Inhibidores de tyk2 y sus usos.
MX2023009685A (es) Inhibidores de tyk2 y sus usos.
MX2025005941A (es) Moduladores de la actividad tnf-\03b1
NZ757081A (en) Somatostatin modulators and uses thereof
PH12022550491A1 (en) Perk inhibiting pyrrolopyrimidine compounds
MX2020007586A (es) Proceso de fabricacion de moduladores de somatostatina.
MY201080A (en) Nlrp3 modulators
WO2022175746A8 (en) Tyk2 inhibitors and uses thereof
MX2025007384A (es) Inhibidores de malt1
WO2019143883A3 (en) Compositions and methods for the treatment of cancer
CA3196916A1 (en) Modulators of the integrated stress pathway
PH12022551052A1 (en) Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
PH12022550497A1 (en) Perk inhibiting compounds